1. Biparatopic anti-PCSK9 antibody enhances the LDL-uptake in HepG2 cells
- Author
-
Xinyang Li, Wei Zhang, Yu Shu, Rui Huo, Chengyang Zheng, Qi Qi, Pengfei Fu, Jie Sun, Yuhuan Wang, Yan Wang, Juxu Lu, Xiangjie Zhao, Guoyou Yin, Qingqing Wang, and Jun Hong
- Subjects
Epitope ,Heavy chain antibody ,LDLR ,LDL-c ,Medicine ,Science - Abstract
Abstract Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising therapeutic target to reduce lipids. In 2020, we reported a chimeric camelid-human heavy chain antibody VHH-B11-Fc targeting PCSK9. Recently, it was verified that VHH-B11 binds one linear epitope in the PCSK9 hinge region. To enhance its druggability, we have developed a novel biparatopic B11-H2-Fc Ab herein. Thereinto, surface plasmon resonance (SPR) confirmed the epitope differences in binding-PCSK9 among VHH-B11, VHH-H2 and the approved Repatha. Additionally, SPR revealed the B11-H2-Fc exhibits an avidity of approximately 0.036 nM for PCSK9, representing a considerable increase compared to VHH-B11-Fc (~ 0.69 nM). Moreover, we found the Repatha and B11-H2-Fc exhibited > 95% PCSK9 inhibition efficiency compared to approximately 48% for the VHH-Fc at 7.4 nM (P 0.05). These findings provide the first evidence of the efficacy of a novel Ab targeting PCSK9 in the field of lipid-lowering drugs.
- Published
- 2024
- Full Text
- View/download PDF